Glioblastoma Review Temodar partnering pipeline drugs

Introduction

According to Datamonitor’s estimate, nearly 30,000 new cases of glioblastoma are expected to be diagnosed in the 7 major pharmaceutical markets in 2003. This Brief examines the currently available treatment for glioblastoma, comprising surgery, radiotherapy and chemotherapy, and key drugs currently in development for glioblastoma, supported by an opinion leader’s views on the pipeline drugs. 

Scope

Overview of current treatment modalities of glioblastoma, including surgery and radiotherapy 

Detailed analysis of commonly used drug regimens for glioblastoma 

Analysis of drugs in development for glioblastoma, including those in phase II and above 

Opinions on current and pipeline drugs from a leading physician in the field of brain tumor 

Report Highlights

Incidence of glioblastoma is set to increase significantly as the proportion of elderly population increases 

Temodar may creep into first-line usage in combination with surgery and radiotherapy 

Opinion leader remains pessimistic about the potential of pipeline drugs for glioblastoma 

Reasons to Purchase

Determine the market potential of glioblastoma by assessing the epidemiology of the disease 

Estimate the commercial potential of pipeline drugs for glioblastoma to determine the viability of entry into the market 

Enhance your commercial positioning by understanding the dynamics of current glioblastoma drugs 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a250